Roivant Sciences Ltd. (ROIV) Earnings Call Transcripts
Roivant Sciences Ltd.'s Latest Earnings Call - June 9, 2026
In Q2 FY2026, Roivant Sciences Ltd. highlighted its strategic focus on late-stage drug development and commercialization, particularly with its lead asset, brepocitinib, which is pending FDA approval with a PDUFA date in September 2026. The company did not disclose specific revenue or earnings figures during the call, nor did it provide updated financial guidance. However, the focus was on the potential market impact of brepocitinib in treating dermatomyositis and other orphan inflammatory diseases. Management emphasized their unique Vant model and the progress in building a specialized sales force, which could significantly influence future revenue streams.
Reported metrics
| Metric | Value |
|---|---|
| PDUFA Date for Brepocitinib | September 2026 (neutral) |
| Patient Population for Dermatomyositis | 70,000 in the U.S. (positive) |
| FcRn Program Indications | Graves' disease, rheumatoid arthritis (positive) |
| Mosliciguat Phase IIb Data | Expected in H2 2026 (neutral) |
Guidance from management
Management did not provide specific financial guidance but expressed confidence in the upcoming launch of brepocitinib and the continued development of their FcRn programs. They emphasized the potential for brepocitinib to achieve blockbuster status across multiple indications.
What management said
Across all of the indications. Look, I think it goes beyond those indications, too. Again, I think if it is inflammatory and has between [ 20,000 and 150,000 ] patients, it ought to be an eligible indication for us. I think over time, we could be in quite a large number of diseases. We have IP as it stands out to 2039. If each indication we're in is a low blockbuster indication, you can just start adding things up ...
We haven't given an answer to that question. But I think in general, our mind is on pricing comparably to in the same range as other FcRns and this is a refractory population that has no other therapeutic options. And so there are definitely large subsets of that population for which I think that price point could be sustained.
What analysts pressed on
Analysts expressed interest in the commercialization strategy for brepocitinib, particularly regarding pricing and market penetration. There were also questions about the competitive landscape for FcRn therapies and the potential impact of emerging degraders in the Graves' disease market.
Main topics on the call
- Brepocitinib Commercialization — Brepocitinib is positioned as a dual inhibitor of JAK1 and TYK2, targeting orphan inflammatory diseases like dermatomyositis. Management is optimistic about its approval and market potential, citing 'great' data and cons...
- Vant Model Strategy — Roivant continues to leverage its Vant model, organizing programs within separate subsidiaries to enhance execution. CEO Matthew Gline stated, 'every time we deviate from that model, we get worse from an execution perspe...
- FcRn Development Strategy — The company is advancing its FcRn franchise, with a focus on developing a best-in-class agent for indications like Graves' disease and rheumatoid arthritis. Gline noted, 'we have carved out a path either where we were fi...
- Mosliciguat Phase IIb Expectations — Mosliciguat, an inhaled sGC activator, is being developed for pulmonary hypertension in lung disease patients. Management is cautiously optimistic, citing the mechanism's potential despite past failures of systemic sGC s...
Read the full Roivant Sciences Ltd. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 76 calls on record spanning January 10, 2022 to June 9, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 76 Roivant Sciences Ltd. earnings call transcripts on record, spanning January 10, 2022 to June 9, 2026. Based on this history, Roivant Sciences Ltd. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ROIV
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 76
- First call
- January 10, 2022
- Most recent
- June 9, 2026
- Reporting cadence
- quarterly